SHANGHAI and CAMBRIDGE, Mass, Nov. 14, 2026 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings,...
LanguageLine Solutions (LLS) Continues to Lead the Language Services Market, Setting Global Standards and Best Practices for a Rapidly Growing Industry SAN ANTONIO, Dec....